Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Pancreatic Neoplasms 22Lymphoma, Large B-Cell, Diffuse 22Glioma 20Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 17Glioblastoma 17Multiple Myeloma 16Colorectal Neoplasms 14Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Mouth Neoplasms 11Lymphoma, Mantle-Cell 11Triple Negative Breast Neoplasms 10Oropharyngeal Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma 10Ovarian Neoplasms 9Laryngeal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Lymphoma, B-Cell 7Hypopharyngeal Neoplasms 7

Interventions

Doxorubicin 4pembrolizumab 3Specimen Handling 3toripalimab 2Ifosfamide 2Biopsy 2silmitasertib 1selinexor 1peposertib 1pemigatinib 1pazopanib 1palbociclib 1mirdametinib 1liposomal doxorubicin 1abemaciclib 1X-Rays 1Vincristine 1Trabectedin 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy 1Quality of Life 1Proton Therapy 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1Injections 1Histamine H2 Antagonists 1Gemcitabine 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡